CLINICAL RESPONSE TO ANTIDEPRESSANTS: CLINICAL EXOME PANEL (Sec. & CNVs) – 3 genes

The Clinical Response to Antidepressants panel (amitriptyline, bupropion, citalopram, clomipramine, desipramine, doxepin, escitalopram, fluvoxamine, imipramine, mirtazapine, nortriptyline, paroxetine, risperidone, sertraline, trimipramine, venlafaxine, vortioxetine) evaluates genetic variants that modulate the metabolism, efficacy, and tolerability of various tricyclic antidepressants, SSRIs, SNRIs, and antipsychotics with serotonergic or dopaminergic action. The metabolism of these drugs depends primarily on the CYP2D6, CYP2C19, and CYP2B6 isoenzymes, whose activity varies among individuals and determines whether a patient is a slow, intermediate, rapid, or ultrarapid metabolizer. These differences affect plasma drug levels, therapeutic response, and the risk of adverse effects. The study allows for personalized treatment selection, avoiding ineffectiveness or toxicity and facilitating dose adjustment based on the patient's genetic profile. Key genes analyzed: CYP2D6, CYP2C19, and CYP2B6.